268 related articles for article (PubMed ID: 33074386)
1. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
2. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for hypoxia
Zhao H; Meng L; Liao X; Liu Y; Mo X; Gong M; Liao Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jul; 47(7):829-838. PubMed ID: 36039578
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Tresch NS; Fuchs D; Morandi L; Tonon C; Rohrer Bley C; Nytko KJ
Vet Med Sci; 2021 Nov; 7(6):2124-2134. PubMed ID: 34477324
[TBL] [Abstract][Full Text] [Related]
5. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
[TBL] [Abstract][Full Text] [Related]
6. Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.
Chernov AN; Kim AV; Skliar SS; Fedorov EV; Tsapieva AN; Filatenkova TA; Chutko AL; Matsko MV; Galimova ES; Shamova OV
Cancer Chemother Pharmacol; 2024 May; 93(5):455-469. PubMed ID: 38280033
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Staniszewska AD; Pilger D; Gill SJ; Jamal K; Bohin N; Guzzetti S; Gordon J; Hamm G; Mundin G; Illuzzi G; Pike A; McWilliams L; Maglennon G; Rose J; Hawthorne G; Cortes Gonzalez M; Halldin C; Johnström P; Schou M; Critchlow SE; Fawell S; Johannes JW; Leo E; Davies BR; Cosulich S; Sarkaria JN; O'Connor MJ; Hamerlik P
Clin Cancer Res; 2024 Apr; 30(7):1338-1351. PubMed ID: 37967136
[TBL] [Abstract][Full Text] [Related]
8. Folic acid-decorated astrocytes-derived exosomes enhanced the effect of temozolomide against glioma.
Liu HM; Zhang Y
Kaohsiung J Med Sci; 2024 May; 40(5):435-444. PubMed ID: 38482902
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Lu VM; Jue TR; McDonald KL
Sci Rep; 2020 Oct; 10(1):18156. PubMed ID: 33097778
[TBL] [Abstract][Full Text] [Related]
11. Apigenin and Temozolomide Synergistically Inhibit Glioma Growth Through the
Wang D; Wang Z; Dai X; Zhang L; Li M
Cancer Biother Radiopharm; 2024 Mar; 39(2):125-132. PubMed ID: 33471569
[No Abstract] [Full Text] [Related]
12. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Lamb LS; Pereboeva L; Youngblood S; Gillespie GY; Nabors LB; Markert JM; Dasgupta A; Langford C; Spencer HT
Sci Rep; 2021 Oct; 11(1):21133. PubMed ID: 34702850
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Golebiewska A; Hau AC; Oudin A; Stieber D; Yabo YA; Baus V; Barthelemy V; Klein E; Bougnaud S; Keunen O; Wantz M; Michelucci A; Neirinckx V; Muller A; Kaoma T; Nazarov PV; Azuaje F; De Falco A; Flies B; Richart L; Poovathingal S; Arns T; Grzyb K; Mock A; Herold-Mende C; Steino A; Brown D; May P; Miletic H; Malta TM; Noushmehr H; Kwon YJ; Jahn W; Klink B; Tanner G; Stead LF; Mittelbronn M; Skupin A; Hertel F; Bjerkvig R; Niclou SP
Acta Neuropathol; 2020 Dec; 140(6):919-949. PubMed ID: 33009951
[TBL] [Abstract][Full Text] [Related]
14. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Juric V; Düssmann H; Lamfers MLM; Prehn JHM; Rehm M; Murphy BM
Cells; 2021 May; 10(5):. PubMed ID: 34066147
[TBL] [Abstract][Full Text] [Related]
16. MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines.
Malacrida A; Di Domizio A; Bentivegna A; Cislaghi G; Messuti E; Tabano SM; Giussani C; Zuliani V; Rivara M; Nicolini G
Biology (Basel); 2022 Jan; 11(1):. PubMed ID: 35053068
[TBL] [Abstract][Full Text] [Related]
17. Effectively α-Terpineol Suppresses Glioblastoma Aggressive Behavior and Downregulates KDELC2 Expression.
Jin JS; Chou JM; Tsai WC; Chen YC; Chen Y; Ong JR; Tsai YL
Phytomedicine; 2024 May; 127():155471. PubMed ID: 38452695
[TBL] [Abstract][Full Text] [Related]
18. MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide.
Bobustuc GC; Kassam AB; Rovin RA; Jeudy S; Smith JS; Isley B; Singh M; Paranjpe A; Srivenugopal KS; Konduri SD
Oncotarget; 2018 Jul; 9(51):29727-29742. PubMed ID: 30038716
[TBL] [Abstract][Full Text] [Related]
19. Role of autophagy in regulation of glioma stem cells population during therapeutic stress.
Abbas S; Singh SK; Saxena AK; Tiwari S; Sharma LK; Tiwari M
J Stem Cells Regen Med; 2020; 16(2):80-89. PubMed ID: 33414584
[TBL] [Abstract][Full Text] [Related]
20. A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.
Ozawa T; Rodriguez M; Zhao G; Yao TW; Fischer WN; Jandeleit B; Koller K; Nicolaides T
Cureus; 2021 Aug; 13(8):e17595. PubMed ID: 34646647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
